Newbury Pharmaceuticals is strengthening its portfolio with Levodopa/Benserazide

MFN Publicerad: 22 Sep 2023 10:00

Newbury Pharmaceuticals is pleased to announce the successful enlargement of the portfolio with the addition of Levodopa/Benserazide tablets.

“This combination of medicines is used to treat Parkinson’s disease. People with Parkinson’s disease do not have enough dopamine in certain parts of their brains. This can result in slow movements, stiff muscles and tremor. With the addition of Levodopa/Benserazide we have also secured a new partnership which can be used to source additional new products” says Mr Lars Minor CEO, Newbury Pharmaceuticals.

Regulatory filling will take place in the near future, and we aim to launch this medicine in Sweden where the total annual value of the market is estimated to be 4 MEUR according to DLMI Nordic Pharma Insights.

Newbury currently has over thirty (30) products in its portfolio and the first launches took place in 2022 with additional launches planned in a steady stream over the coming years.

About Newbury Pharmaceuticals

Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury aims to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging experience and extensive international network. Newbury offers strategic partnerships of innovation for the benefit of the Nordic healthcare market.

Västra Hamnen Corporate Finance is the Company's Certified Adviser on Nasdaq First North and can be reached at [email protected] or +46 (0) 40 200 250.

Börskollen

För dig med koll på börsen

Pressmeddelande

Newbury Pharmaceuticals is strengthening its portfolio with Levodopa/Benserazide

Bifogade filer

Nyheter om Newbury Pharmaceuticals

Läses av andra just nu

Om aktien Newbury Pharmaceuticals

Senaste nytt